Goodwin advised BridgeBio Pharma on the transaction BridgeBio Pharma as launched a new subsidiary, QED Therapeutics, to drive the development of infigratinib (BGJ398), a highly potent…
Establishment of QED Therapeutics
Goodwin advised BridgeBio Pharma on the transaction BridgeBio Pharma as launched a new subsidiary, QED Therapeutics, to drive the development of infigratinib (BGJ398), a highly potent…